Brazil Patent Agreement Hopes To Increase Flow Of Generics To Market
Executive Summary
Joint ordinance signed by Anvisa and INPI hopes to resolve a 16-year impasse between the two agencies and bring predictability to patent application process; Anvisa will be relegated to analyzing public health matters, while INPI will make final patentability determinations.
You may also be interested in...
Brazil's Product Licensing Restrictions Eventually May Get Easier
Brazilian drug regulator Anvisa has made some changes over the years, but still restricts companies with approved Rx products from licensing them to another company.
Brazil’s New Patent Agreement Is “Real and Concrete Threat” To IP
An agreement between Brazil’s medicines regulator, ANVISA, and the National Institute of Industrial Property, INPI, aimed at clearly defining their respective roles in the patent application process could pose a threat to the patent system, say IPR experts.
Biodiversity Law Reform Spurs Innovation, But Patent Backlog Remains
Brazil's new biodiversity research law is viewed as a step toward fostering biological innovation, but patent backlogs of 14 years still prove to be a major deterrent to conducting R&D in the country.